Skip to main content

Table 1 Demographics and clinical characteristics of ALS (A,B,C) and healthy control (D) individuals included in the discovery proteomics (A, B) and in the re-test immunoassays (C, D)

From: Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis

A. DISCOVERY EXPERIMENT: ALS PLASMA SAMPLES
ALS
type
ALSFRS-R
early
ALSFRS-R
late
Gender
M/F
Age at onset (years) PRL Time from onset to death or last visit (months) Time from onset to first sample (months) Time between first and last sample (months) Site of disease onset
limb/ bubar
Slow (n = 6) 43
(41–45)
31.5
(27–35)
5 M / 1F 58.1 (35–71) 0.25
(0.1–0.4)
107
(97, 254)
76
(30–192)
58
(48–69)
4 limb /2 bulbar
Fast
(n = 6)
43.8
(41–46)
28.6
(22–35)
3 M / 3F 61.3 (48–67) 1.5 (1–1.9) 20.5 (11–32) 10.2
(5–19)
13.8 (7–22) 3 limb /3 bulbar
B. DISCOVERY EXPERIMENT: ALS PBMC SAMPLE TO FORM THE REFERENCE POOL
ALS
Pool
ALSRS-R Gender
M/F
Age at onset (years) PRL Time from onset to death or last visit (months) Time from onset to sampling (months) Site of disease onset limb/ bubar
Slow(3)
Fast (2)
n = 5
31
(22–42)
3 M /2 F 65.8 (57–68) 0.8
(0.02–2.5)
64.6
(8–120)
19
(7–44)
3 limb /2 bulbar
C. RE-TEST EXPERIMENT: ALS PLASMA SAMPLES
ALS type ALSRS-R Gender
M/F
Age at onset (years) PRL Time from onset to death or last visit (months) Time from onset to sampling (months) Site of disease onset limb/ bubar
Slow
(n = 23)
39
(18–47)
18 M / 5F 65.25 (37–86.9) 0.216 (0.03–0.47) 120.4
(28–335.2)
62.8
(7–248.8)
15 limb /8 bulbar
Fast
(n = 24)
33
(13–43)
8 M / 16F 62.8 (34.8–82.4) 1.48 (0.74–3.6) 28.1
(5–50)
14.8
(2.8–29.8)
13 limb /11 bulbar
D. RE-TEST EXPERIMENT: HEALTHY CONTROLS PLASMA SAMPLES
n = 29 Gender M/F Age at sampling (years)
8 M / 17F 60.9 (50.8–73)